Clinical validation of novel RNA fusion detection for NSCLC with SOPHiA DDM tm Dx RNAtarget Oncology

Clinical validation of novel RNA fusion detection for NSCLC with SOPHiA DDMTM Dx RNAtarget Oncology Solution

Prof. Alexander Harlé, PhD 

Biologist/Professor of liquid biopsy and tumor heterogeneity group, Institut de Cancérologie de Lorraine-Alexis Vautrin ​

Enabling clinical workflows in Trusted Research Environments ​

Gaetano Bonifacio, PhD 

Industry Advisor-Healthcare, Microsoft

Disclaimer notice:

The term SOPHIA used by the speaker refers to SOPHiA GENETICS and its products.
The opinions expressed during this presentation are those of the speaker and may not represent the opinions of SOPHiA GENETICS. SOPHiA GENETICS does not provide support in the validation of custom products for clinical use. SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us atsupport@sophiagenetics.com to obtain the appropriate product information for your country of residence.

Event Date
September 10, 2022 – September 10, 2022

Event Type

Event Location

Europe

Areas of Interest

Your content goes here. Edit or remove this text inline or in the module Content settings. You can also style every aspect of this content in the module Design settings and even apply custom CSS to this text in the module Advanced settings.

pink dots icon

Want to know more?
Get in touch with us.

Our client services team is on hand to help.
';